BACKGROUND: Relatives donating peripheral blood stem cells (PBSCs) may be accepted for donation on less strict criteria than unrelated donors. We evaluated the occurrence of adverse events during procedure and follow-up, with a special focus on donors who would have been deferred as unrelated donors. STUDY DESIGN AND METHODS: All 268 related PBSC donors at our center (1996-2006) were included. Data were retrospectively collected from medical reports and standard follow-up. Health questionnaires were sent from 2007. Medical outcomes of donors, deferrable or eligible according to international criteria for unrelated donation, were compared. RESULTS: Forty donors (15%) would have been deferred for unrelated donation. Short-term adverse events occurred in 2% of procedures. Questionnaires were returned by 162 (60%) donors on average 7.5 years after donation, bringing total person-years of follow-up to 1278 (177 in deferrable donors). Nine malignancies and 14 cardiovascular events were reported. The incidence rate of cardiovascular events in eligible donors was 6.5 (95% confidence interval [CI], 2.5-12.3) per 1000 person-years compared to 44.9 (95% CI, 17.4-85.2) in deferrable donors; incidence rates of malignancies were 4.6 (1.4-9.6) and 24.0 (6.0-53.9) per 1000 person-years, respectively, in eligible and deferrable donors. All incidence rates were within the range of age- and sex-matched general population. No autoimmune disorders were reported. CONCLUSION: In both the eligible and the deferrable related donors treated with granulocyte-colony-stimulating factor there are few short-term and long-term problems. The occurrence of post-PBSC cardiovascular events and malignant disease in related donors appears to be within the range of the general population.
BACKGROUND: Relatives donating peripheral blood stem cells (PBSCs) may be accepted for donation on less strict criteria than unrelated donors. We evaluated the occurrence of adverse events during procedure and follow-up, with a special focus on donors who would have been deferred as unrelated donors. STUDY DESIGN AND METHODS: All 268 related PBSC donors at our center (1996-2006) were included. Data were retrospectively collected from medical reports and standard follow-up. Health questionnaires were sent from 2007. Medical outcomes of donors, deferrable or eligible according to international criteria for unrelated donation, were compared. RESULTS: Forty donors (15%) would have been deferred for unrelated donation. Short-term adverse events occurred in 2% of procedures. Questionnaires were returned by 162 (60%) donors on average 7.5 years after donation, bringing total person-years of follow-up to 1278 (177 in deferrable donors). Nine malignancies and 14 cardiovascular events were reported. The incidence rate of cardiovascular events in eligible donors was 6.5 (95% confidence interval [CI], 2.5-12.3) per 1000 person-years compared to 44.9 (95% CI, 17.4-85.2) in deferrable donors; incidence rates of malignancies were 4.6 (1.4-9.6) and 24.0 (6.0-53.9) per 1000 person-years, respectively, in eligible and deferrable donors. All incidence rates were within the range of age- and sex-matched general population. No autoimmune disorders were reported. CONCLUSION: In both the eligible and the deferrable related donors treated with granulocyte-colony-stimulating factor there are few short-term and long-term problems. The occurrence of post-PBSC cardiovascular events and malignant disease in related donors appears to be within the range of the general population.
Authors: C Anthias; S M van Walraven; B S Sørensen; G N de Faveri; M Fechter; J Cornish; A Bacigalupo; C Müller; M Boo; B E Shaw Journal: Bone Marrow Transplant Date: 2015-03-02 Impact factor: 5.483
Authors: Chloe Anthias; Paul V O'Donnell; Deidre M Kiefer; Jean Yared; Maxim Norkin; Paolo Anderlini; Bipin N Savani; Miguel A Diaz; Menachem Bitan; Joerg P Halter; Brent R Logan; Galen E Switzer; Michael A Pulsipher; Dennis L Confer; Bronwen E Shaw Journal: Biol Blood Marrow Transplant Date: 2015-11-18 Impact factor: 5.742
Authors: Chloe Anthias; Bronwen E Shaw; Deidre M Kiefer; Jane L Liesveld; Jean Yared; Rammurti T Kamble; Anita D'Souza; Peiman Hematti; Matthew D Seftel; Maxim Norkin; Zachariah DeFilipp; Kimberly A Kasow; Muneer H Abidi; Bipin N Savani; Nirali N Shah; Paolo Anderlini; Miguel A Diaz; Adriana K Malone; Joerg P Halter; Hillard M Lazarus; Brent R Logan; Galen E Switzer; Michael A Pulsipher; Dennis L Confer; Paul V O'Donnell Journal: Biol Blood Marrow Transplant Date: 2015-11-18 Impact factor: 5.742
Authors: Simon Pahnke; Ulla Axdorph Nygell; Jan-Erik Johansson; Annika Kisch; Per Ljungman; Anna Sandstedt; Hans Hägglund; Gunnar Larfors Journal: Bone Marrow Transplant Date: 2022-03-07 Impact factor: 5.174